Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
687 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02736513 | Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases | unknown | Phase 2 | 40 | Soroka University Medical CenterOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT04521075 | A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC | unknown | Phase 1 / Phase 2 | 42 | Ella Therapeutics LtdINDUSTRY | 1 | Aug 16, 2021 |
| clinicaltrials |
| NCT00742027 | Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma | completed | Phase 2 | 129 | Novartis PharmaceuticalsINDUSTRY | 13 | Jul 28, 2021 | clinicaltrials |
| NCT01676259 | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer(PROTACT) | unknown | Phase 2 | 80 | Silenseed LtdINDUSTRY | 2 | Jul 2, 2021 | clinicaltrials |
| NCT04934930 | Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status(FLMRD) | unknown | Phase 2 | 40 | Meir Medical CenterOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT01211483 | Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 222 | Daiichi SankyoINDUSTRY | 13 | Jun 16, 2021 | clinicaltrials |
| NCT02574637 | Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease | terminated | Phase 2 | 29 | AstraZenecaINDUSTRY | 12 | May 26, 2021 | clinicaltrials |
| NCT04334993 | Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study | unknown | Phase 2 | 110 | Israeli Medical AssociationOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT01610336 | A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment | completed | Phase 2 | 161 | Novartis PharmaceuticalsINDUSTRY | 14 | Apr 8, 2021 | clinicaltrials |
| NCT01915602 | Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 14 | BayerINDUSTRY | 21 | Apr 8, 2021 | clinicaltrials |
| NCT01231659 | Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | completed | Phase 2 | 72 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 26, 2021 | clinicaltrials |
| NCT00495079 | Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | completed | Phase 2 | 65 | Spectrum Pharmaceuticals, IncINDUSTRY | 5 | Mar 5, 2021 | clinicaltrials |
| NCT04671407 | The Aim of This Study is to Compare the Efficacy of Perioperative Hypertonic Saline 3% Versus Normal Saline (0.9%) in Decreasing Recurrence Risk in Non-muscle Invasive Bladder Cancer | unknown | Phase 2 | 150 | Kaplan Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT04383067 | A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | unknown | Phase 2 | 20 | Sheba Medical CenterOTHER_GOV | 1 | Feb 11, 2021 | clinicaltrials |
| NCT00285051 | Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy | terminated | Phase 2 | 6 | Rafa LaboratoriesINDUSTRY | 1 | Dec 23, 2020 | clinicaltrials |
| NCT02308020 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | completed | Phase 2 | 162 | Eli Lilly and CompanyINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT02772198 | T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies | unknown | Phase 1 / Phase 2 | 300 | Sheba Medical CenterOTHER_GOV | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03591276 | Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer(KEYDOX) | recruiting | Phase 1 / Phase 2 | 15 | Shaare Zedek Medical CenterOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT02207530 | Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 112 | AstraZenecaINDUSTRY | 14 | Sep 29, 2020 | clinicaltrials |
| NCT02319044 | Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 267 | AstraZenecaINDUSTRY | 15 | Sep 29, 2020 | clinicaltrials |
| NCT03820908 | Bisantrene for Relapsed /Refractory AML | completed | Phase 2 | 10 | Sheba Medical CenterOTHER_GOV | 1 | Aug 7, 2020 | clinicaltrials |
| NCT03059615 | A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS | withdrawn | Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Jul 31, 2020 | clinicaltrials |
| NCT04376931 | A Prospective Dose Finding Study of Iscador Infusion | unknown | Phase 1 / Phase 2 | 24 | HaEmek Medical Center, IsraelOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT01701479 | Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)(LTI) | unknown | Phase 1 / Phase 2 | 288 | St. Anna KinderkrebsforschungOTHER | 7 | Jul 14, 2020 | clinicaltrials |
| NCT01446159 | Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer | completed | Phase 2 | 188 | MedImmune LLCINDUSTRY | 11 | Jun 2, 2020 | clinicaltrials |
| NCT01260506 | Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 75 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 2 | Apr 24, 2020 | clinicaltrials |
| NCT02541604 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | Hoffmann-La RocheINDUSTRY | 11 | Feb 25, 2020 | clinicaltrials |
| NCT02280694 | Low Dose Metronomic Poly-chemotherapy for Metastatic CRC(LDMchemoCRC) | completed | Phase 2 | 45 | HaEmek Medical Center, IsraelOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT02414165 | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma(Toca5) | terminated | Phase 2 / Phase 3 | 403 | Tocagen Inc.INDUSTRY | 4 | Feb 7, 2020 | clinicaltrials |
| NCT01681823 | Effect of Modified Citrus Pectin on PSA Kinetics in Biochemical Relapsed PC With Serial Increases in PSA | completed | Phase 2 | 60 | EcoNugenicsINDUSTRY | 1 | Jan 29, 2020 | clinicaltrials |
| NCT01484275 | A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma | completed | Phase 2 | 85 | Janssen Research & Development, LLCINDUSTRY | 11 | Jan 27, 2020 | clinicaltrials |
| NCT00558675 | A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy | completed | Phase 1 / Phase 2 | 6 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01923233 | In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01995227 | An Individualized Anti-Cancer Vaccine Study in Patients With HCC | withdrawn | Phase 1 / Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02465528 | Ceritinib Rare Indications Study in ALK+ Tumors | terminated | Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 27, 2019 | clinicaltrials |
| NCT01802879 | Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 6, 2019 | clinicaltrials |
| NCT00628251 | Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer(ICEBERG 3) | completed | Phase 2 | 97 | AstraZenecaINDUSTRY | 9 | Dec 5, 2019 | clinicaltrials |
| NCT04182594 | Cardiovascular Events in GnRH Agonist vs. Antagonist | unknown | Phase 2 | 80 | Rabin Medical CenterOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT02828878 | Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 12 | Cellect BiotechnologyINDUSTRY | 1 | Nov 26, 2019 | clinicaltrials |
| NCT02981342 | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | completed | Phase 2 | 106 | Eli Lilly and CompanyINDUSTRY | 8 | Nov 20, 2019 | clinicaltrials |
| NCT03838029 | Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery(BC-PC) | unknown | Phase 2 | 210 | Assaf-Harofeh Medical CenterOTHER_GOV | 1 | Nov 20, 2019 | clinicaltrials |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma(LAPC-BC-819) | terminated | Phase 2 | 12 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Nov 1, 2019 | clinicaltrials |
| NCT00643565 | A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma. | completed | Phase 2 | 154 | Hoffmann-La RocheINDUSTRY | 14 | Oct 22, 2019 | clinicaltrials |
| NCT01232452 | A Study in Non-Small Cell Lung Cancer | completed | Phase 2 | 172 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 20, 2019 | clinicaltrials |
| NCT01505530 | A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer | completed | Phase 2 | 125 | Eli Lilly and CompanyINDUSTRY | 5 | Sep 18, 2019 | clinicaltrials |
| NCT01900652 | A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants(Chime) | completed | Phase 2 | 111 | Eli Lilly and CompanyINDUSTRY | 10 | Sep 18, 2019 | clinicaltrials |
| NCT00875667 | A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)(Sprint) | completed | Phase 2 | 254 | CelgeneINDUSTRY | 14 | Sep 16, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials